Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of INO-6160 (DNA vaccine encoding native-like HIV Env trimer and interleukin-12) given alone or with a 3M-052-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• 3M-052 AF (TLR7/8 agonist adjuvant)
• INO-6160 (DNA vaccine encoding native-like HIV Env trimer and interleukin-12)
• VRC HIV Env Trimer 4571 (HIV Env trimer 4571)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1-infection | Phase 1 | Status: COMPLETED | Results posted: 2025-07-04